These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The value of preserving HIV-specific immune responses.
    Author: Kaufmann DE, Rosenberg ES.
    Journal: J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711.
    Abstract:
    HIV-1 infection is characterised by persistent viraemia and a progressive decline in both number and function of CD4 T-helper lymphocytes. The inability to contain viral replication presumably results from the lack of an effective HIV-1-specific immune response observed in most HIV-infected individuals. The persistent viraemia and decline in the number and function of CD4 cells lead to a further loss of immunity to HIV-1 as well as to opportunistic pathogens. Highly active antiretroviral therapy (HARRT) has been shown to reconstitute pathogen-specific immune responses in a majority of subjects, with a dramatic drop in the morbidity and mortality caused by opportunistic infections. By contrast, HIV-1-specific immunity remains largely ineffective and most people with chronic HIV-1 infection cannot control viraemia after interruption of HARRT, indicating a need to develop new strategies to maintain and improve HIV-1-specific immunity. Here we review the relative role of CD4 T-helper cells in the immune response against HIV infection and their contribution to cell-mediated immune responses to other pathogens infecting people with AIDS. In addition, we discuss the concepts of: supervised treatment interruptions, therapeutic and preventive vaccination, optimisation of antigen presentation and T-cell priming by ex vivo stimulated and expanded dendritic cells.
    [Abstract] [Full Text] [Related] [New Search]